ReviewArchives of gynecology and obstetrics2022

The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.

Xue Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.